Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
<p></p><div> <p>Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatmen...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513565682040832 |
|---|---|
| author | Ahmad Al Bishawi (14148810) |
| author2 | Hamad Abdel Hadi (14777272) Eman Elmekaty (14777932) Musaed Al Samawi (12535539) Arun Nair (401341) Mohammed Abou Kamar (14777935) Muna Al Maslamani (12501671) Alaaeldin Abdelmajid (12535542) |
| author2_role | author author author author author author author |
| author_facet | Ahmad Al Bishawi (14148810) Hamad Abdel Hadi (14777272) Eman Elmekaty (14777932) Musaed Al Samawi (12535539) Arun Nair (401341) Mohammed Abou Kamar (14777935) Muna Al Maslamani (12501671) Alaaeldin Abdelmajid (12535542) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ahmad Al Bishawi (14148810) Hamad Abdel Hadi (14777272) Eman Elmekaty (14777932) Musaed Al Samawi (12535539) Arun Nair (401341) Mohammed Abou Kamar (14777935) Muna Al Maslamani (12501671) Alaaeldin Abdelmajid (12535542) |
| dc.date.none.fl_str_mv | 2023-03-16T06:21:16Z |
| dc.identifier.none.fl_str_mv | 10.1002/ccr3.5467 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Remdesivir_for_COVID_19_pneumonia_in_patients_with_severe_chronic_kidney_disease_A_Case_series_and_review_of_the_literature/22257898 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology General Medicine |
| dc.title.none.fl_str_mv | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p></p><div> <p>Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.</p> </div><p></p><h2>Other Information</h2> <p> Published in: Clinical Case Reports<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/ccr3.5467" target="_blank">http://dx.doi.org/10.1002/ccr3.5467</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_57c8b3847104fb97d8776367edea34f7 |
| identifier_str_mv | 10.1002/ccr3.5467 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22257898 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literatureAhmad Al Bishawi (14148810)Hamad Abdel Hadi (14777272)Eman Elmekaty (14777932)Musaed Al Samawi (12535539)Arun Nair (401341)Mohammed Abou Kamar (14777935)Muna Al Maslamani (12501671)Alaaeldin Abdelmajid (12535542)Biomedical and clinical sciencesCardiovascular medicine and haematologyGeneral Medicine<p></p><div> <p>Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.</p> </div><p></p><h2>Other Information</h2> <p> Published in: Clinical Case Reports<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/ccr3.5467" target="_blank">http://dx.doi.org/10.1002/ccr3.5467</a></p>2023-03-16T06:21:16ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/ccr3.5467https://figshare.com/articles/journal_contribution/Remdesivir_for_COVID_19_pneumonia_in_patients_with_severe_chronic_kidney_disease_A_Case_series_and_review_of_the_literature/22257898CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222578982023-03-16T06:21:16Z |
| spellingShingle | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature Ahmad Al Bishawi (14148810) Biomedical and clinical sciences Cardiovascular medicine and haematology General Medicine |
| status_str | publishedVersion |
| title | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| title_full | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| title_fullStr | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| title_full_unstemmed | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| title_short | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| title_sort | Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology General Medicine |